Vaccine Research Center Seminar Series, Winter 2012
Vaccine Research Center Seminar Series, Winter 2012:
Jan 24 Jeff Cohen NIAID, NIH - Herpes simplex virus 2 vaccines: Beyond glycoprotein
Jan 31 Chris Walker Ohio State University - Immune control of persistent hepatitis C virus infection
Feb 7 Fred Alt Harvard University - High throughput analysis of mechanisms that influence [...]
Sinovac Begins the Phase III Clinical Trial for its EV71 Vaccine Against Hand, Foot and Mouth Disease
Sinovac Biotech Ltd.begins the phase III clinical trial for its proprietary inactivated EV71 vaccine against hand, foot and mouth disease (HFMD). The Phase II trial, completed in November 2011, confirmed favorable safety and tolerance profiles, and good immunogenicity. According to the results of phase II clinical trial, the formulation of 400U with aluminum adjuvant was [...]
U.S. Military Research Center Develops Breast Cancer Vaccine
Military researchers here have developed a cutting-edge cancer vaccine that’s slashing breast cancer recurrence rates and giving some survivors a better shot at a cancer-free future. After more than a decade of research and testing, the cancer vaccine, dubbed E-75, soon will move on to its final phase of testing to earn Food and Drug [...]
Promise of Lifetime Flu Vaccine
SEEK, a UK privately-owned drug-discovery group, reports preliminary successful trials of a new vaccine that provides lifetime protection against all influenza strains after single vaccination. The Seek’s press release says that the Universal Flu vaccine could be available for use in the next 3-5 years.
The 2012 Integrated Medical, Public Health, Preparedness and Response Training Summit, May 21-25, 2012 Nashville, Tennessee
The 2012 Integrated Medical, Public Health, Preparedness and Response Training Summit will be held May 21-25 in Nashville, Tennessee. This training summit brings together HHS partners including the National Disaster Medical System (NDMS), the Medical Reserve Corps (MRC), the Emergency System for Advance Registration of Volunteer Health Professionals (ESAR-VHP), and the United States Public [...]
Business Strategies for Biologics: Positioning and Partnering for the Biopharmaceutical Evolution, October 5-6 2011, Boston, Massachusetts
Business Strategies for Biologics: Positioning and Partnering for the Biopharmaceutical Evolution will be held hosted October 5-6th, 2011 in Boston, Massachusetts. The two day conference will cover on-trend topics regarding the future of pharma, sourcing strategies for biologics, regulatory challenges, and opportunities in biosimilars. Speakers will include senior personnel from Merck, Novartis, Pfizer, Sanofi, Genentech/Roche, [...]
Kite Pharma Raises $15 Million
Kite Pharma, Inc., a biopharmaceutical company focused on developing innovative active immunotherapies for cancer, today announced that it has raised $15 million in an initial round of financing through a private placement with a syndicate of venture and qualified investors. Riverbank Capital Securities Inc., a FINRA member broker dealer, acted as placement agent in connection [...]
HHS releases new strategic plan to advance vaccine and immunization science and policy for the next decade
The U.S. Department of Health and Human Services today unveiled a new National Vaccine Plan to enhance coordination of all aspects of federal vaccine and immunization activities. Its goal is to ensure that all Americans can access the preventive benefits of vaccines.
The plan is a wide-ranging guide to innovating the nation’s vaccine system. It addresses [...]
BARDA Supports Next Steps for a New Antiviral Drug for Smallpox
A $24.8 million federal contract will support development a new antiviral drug to treat smallpox. The Biomedical Advanced Research and Development Authority (BARDA), within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, will fund the contract with Chimerix, Inc., of Durham, N.C. The contract can be [...]
Next Generation Vaccines Conference, October 21-22 2010,Vienna, Austria
The vaccine market represents an increasingly attractive segment characterized by promising vaccine candidates, rising global demand and preparations for the next pandemic influenza. Future potential of the vaccine market will be discussed at Jacob Fleming’s Next Generation Vaccines Conference, taking place in Vienna, Austria on 21st – 22nd October. The latest developments in the prophylactic [...]
